Aethlon Medical's Hemopurifier Advances to Cohort 2, Expands EV Research and Partnerships
- Aethlon is enrolling Cohort 2 in an Australian oncology trial testing Hemopurifier safety and dosing in patients on anti‑PD‑1 therapies.
- Preclinical reports show Hemopurifier's GNA resin binds Long COVID extracellular vesicles and reduces immune‑dysregulating microRNAs.
- Aethlon seeks partnerships and simplified platforms (SLAMB) to enable Hemopurifier use without dialysis machines or nephrologists.
Hemopurifier advances toward broader oncology and extracellular vesicle applications
Aethlon Medical is advancing its Hemopurifier program with active enrollment and treatment in Cohort 2 of an Australian oncology study designed to test safety and feasibility in patients receiving anti‑PD‑1 therapies. The nine‑to‑18 patient trial follows Cohort 1 and evaluates dosing and tolerability in patients with solid tumors whose disease is stable or progressing on Keytruda or Opdivo. The company reports Cohort 1 showed favorable directional improvements in extracellular vesicle (EV) and immune cell numbers alongside acceptable safety and tolerability, supporting continuation into the next cohort.
Concurrently, Aethlon is expanding preclinical work on its EV research platform, highlighting Long COVID data published on bioRxiv and under peer review that show the GNA affinity resin used in the Hemopurifier binds EVs from Long COVID samples and reduces microRNAs associated with immune dysregulation. The firm says additional EV cargo removal pathways by the Hemopurifier are under exploration, positioning the device as potentially applicable to indications beyond oncology where pathogenic EVs play a role. Management frames the Hemopurifier as a “pipeline within a single device,” emphasizing multi‑indication therapeutic potential driven by EV capture and modulation of immune biomarkers.
To support broader clinical adoption, Aethlon enters technology partnerships to test simplified treatment platforms. Under a Material Transfer Agreement, Stavro is evaluating Hemopurifier compatibility with the SLAMB simplified blood treatment system so treatments can be delivered in oncology units and infusion centers without large dialysis catheters, dialysis machines or supervising nephrologists. The company is concurrently pursuing internal technology development to assess additional compatibility with simplified blood treatment platforms to reduce logistical barriers to use.
Operational discipline and corporate standing
Aethlon reports year‑to‑date cost efficiencies that reduce operating expenses versus the prior year and says all prior Nasdaq compliance matters remain resolved, with continued compliance confirmed. The results come in a fiscal third quarter ending Dec. 31, 2025, as the company balances clinical execution with expense management.
Engagement and next steps
Aethlon schedules a conference call for 4:30 p.m. ET on the day of the release to discuss the quarter, ongoing clinical work and technology development, and reiterates its focus on translating preclinical EV findings into clinical benefit. The company continues to prioritize advancing the Hemopurifier in oncology while exploring broader applications through partnership and platform compatibility.